Patients
dysplasia, hip disease, Ficat, ONFH, THA, end-stage osteoarthritis of the hip
HIP DISEASE, DYSPLASIA, OSTEONECROSIS OF THE FEMORAL HEAD
The study was approved by the Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology (2016-S247) and registered in the Chinese Clinical Trial Registry (ChiCTR2000031041, 21/3/2020). All research was performed in accordance with the Declaration of Helsinki and relevant guidelines/regulations. All patients provided written informed consent before participating. Patients undergoing primary bilateral THA at our institution were screened between January 2017 and January 2020. The inclusion criteria were bilateral end-stage osteoarthritis of the hip, bilateral osteonecrosis of the femoral head (ONFH) (Ficat III or IV), or bilateral Crowe Type I or II dysplasia. The exclusion criteria were: (1) unilateral hip disease; (2) prior hip open surgery; (3) body mass index (BMI) > 30 kg/mFlow diagram illustrating patient selection, randomization, follow-up, and data analysis throughout the study. BI-DAA, bikini-incision via direct anterior approach; PLA, posterolateral approach.